|
|
|
|
|
|
Sponsors and Collaborators: |
London School of Hygiene and Tropical Medicine Tropical Medicine Research Institute World Health Organization |
Information provided by: | London School of Hygiene and Tropical Medicine |
ClinicalTrials.gov Identifier: | NCT00330902 |
In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose parasitaemia persists at very low levels throughout the dry season, could be a useful strategy for malaria control in areas with a short transmission season. We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season.
Condition | Intervention | Phase |
Plasmodium Infections |
Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) Drug: primaquine (PQ) plus SP+AS |
Phase III |
MedlinePlus related topics: | Malaria |
ChemIDplus related topics: | Pyrimethamine Sulfadoxine Artesunate Fansidar Primaquine Primaquine phosphate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan |
Enrollment: | 104 |
Study Start Date: | January 2004 |
Study Completion Date: | November 2004 |
Arms | Assigned Interventions |
1: Active Comparator
Sulfadoxine pyrimethamine plus three daily doses of artesunate
|
Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
|
2: Experimental
Sulfadoxine pyrimethamine plus artesunate plus primaquine
|
Drug: primaquine (PQ) plus SP+AS
single dose of primaquine on day 4
|
104 individuals with low density Plasmodium falciparum infection detected by polymerase chain reaction (PCR) were randomized to receive sulfadoxine-pyrimethamine and three daily doses of artesunate (SP+AS) or SP+AS and a dose of primaquine (SP+AS+PQ), and were followed up for 14 days during the transmission-free season in Eastern Sudan. Subjects were visited on days 3, 7 and 14 after the start of treatment to record any adverse events and to detect P.falciparum using PCR. PCR positive samples were tested for gametocytes using RT-PCR. Packed cell volume was measured on days 7 and 14.
Ages Eligible for Study: | 3 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Sudan | |||||
Tropical Medicine Research Institute | |||||
Khartoum, Sudan |
London School of Hygiene and Tropical Medicine |
Tropical Medicine Research Institute |
World Health Organization |
Principal Investigator: | Badria B El Sayed, PhD | TMRI, Khartoum |
Study Chair: | Omer Z Baraka, MD | Faculty of Medicine, University of Khartoum |
Study ID Numbers: | SGS64 |
First Received: | May 25, 2006 |
Last Updated: | October 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00330902 |
Health Authority: | Sudan: Ministry of Health |
|
|
|
|
|